(19)
(11) EP 1 613 610 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
16.12.2009 Bulletin 2009/51

(45) Mention of the grant of the patent:
01.07.2009 Bulletin 2009/27

(21) Application number: 04725341.4

(22) Date of filing: 02.04.2004
(51) International Patent Classification (IPC): 
C07D 271/12(2006.01)
A61K 51/04(2006.01)
 C07D 285/14(2006.01)
(86) International application number:
PCT/EP2004/003517
(87) International publication number:
WO 2004/087684 (14.10.2004 Gazette 2004/42)

(54)

BENZO 1,2,5 OXADIAZOLES AND BENZO 1,2,5 THIADIAZOLES USEFUL AS HISTOPATHOLOGICAL STAINING AGENTS, IMAGING AGENTS AND BIOMARKERS

BENZO¬1,2,5 OXADIAZOLE UND BENZO¬1,2,5 THIADIAZOLE ALS HISTOPATHOLOGISCHE ANFÄRBUNGSMITTEL, ABBILDUNGSMITTEL UND BIOMARKER

BENZO (1,2,5)OXADIAZOLES ET BENZO (1,2,5)THIADIAZOLES UTILISES COMME AGENTS DE COLORATION HISTOPATHOLOGIGUE, AGENTS D'IMAGERIE ET BIOMARQUEURS

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

(30) Priority: 04.04.2003 GB 0307855

(43) Date of publication of application:
11.01.2006 Bulletin 2006/02

(73) Proprietors:
  • Novartis AG
    4056 Basel (CH)
    Designated Contracting States:
    BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL SE PT RO SI SK TR 
  • Novartis Pharma GmbH
    1230 Wien (AT)
    Designated Contracting States:
    AT 

(72) Inventors:
  • AUBERSON, Yves
    CH-4123 Allschwil (CH)
  • HINTERMANN, Samuel
    CH-4056 Basel (CH)
  • ZIMMERMANN, Kaspar
    CH-4104 Oberwil (CH)

(74) Representative: de Weerd, Petrus G.W. et al
Novartis International AG Corporate Intellectual Property
4002 Basel
4002 Basel (CH)


(56) References cited: : 
EP-A- 1 110 945
 WO-A-00/10614
   
  • PATENT ABSTRACTS OF JAPAN vol. 1999, no. 13, 30 November 1999 (1999-11-30) & JP 11 228550 A (DOUJIN KAGAKU KENKYUSHO:KK), 24 August 1999 (1999-08-24)
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).